Manhattan Research Report Provides a Framework for Pharma to Navigate the Physician Social Media Landscape

Manhattan ResearchPharmaceutical and healthcare market research company Manhattan Research releases a new report providing in-depth data and analysis to help healthcare marketers, agencies, and publishers assess the physician social media landscape. The report found that the majority of U.S. physicians are using professional user-generated content in some form, primarily on blogs, open message boards, and other online media. In contrast, less than 20 percent of U.S. physicians have visited closed professional online communities despite high interest in these types of forums, representing a challenge for marketers seeking to leverage social media as an engagement tool. "Physician Social Media: Benchmarking Adoption and Assessing Strategic Opportunities" provides a framework for pharma companies to approach physician social media, discusses why traction of professional communities remains low, and explores challenges and opportunities for harnessing physician use of social media content.

"Framing the social media landscape is a critical first step in understanding the growing audience of physicians interacting with one another online," said James Avallone, Senior Digital Healthcare Analyst at Manhattan Research. "Since physicians' primary consumption of professional social media is happening outside the walls of existing closed physician-only communities, marketers need to evaluate other engagement opportunities, such as distributed content or niche communities."

"Physician Social Media: Benchmarking Adoption and Assessing Strategic Opportunities" draws from Manhattan Research's Taking the Pulse® v10.0 study conducted in Q1 2010 via online and offline survey methodology among 2,033 U.S. practicing physicians.

For more information about the report and its table of contents, please visit http://www.manhattanresearch.com/physician-social-media

About Manhattan Research Reports
Manhattan Research offers in-depth reports on important trends in physician and consumer use of digital media and technology for health. The report series draws from interviews conducted with nearly 20,000 physicians and consumers about their behaviors, attitudes, and future interests as it relates to their use of the Internet and other technologies for health and treatment decisions. Each PDF report includes a written analysis, supporting graphs and data, and strategic takeaways. For more information, please visit http://www.manhattanresearch.com/reports.

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a leading market research and advisory services firm for global pharmaceutical and healthcare companies. For more information, visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.decisionresourcesinc.com.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...